Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX-1777 in Relapsed/Refractory Aggressive T-Cell Malignancies
NCT00035022Phase 2Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Aug 2001
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of desmopressin in T-cell leukemia and T-cell lymphoma, sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Maximum Tolerated Dose, Safety and Tolerability and 1 more. Started Aug 2001; status: completed.
02
Drugs
desmopressin
03
Conditions
T-cell leukemiaT-cell lymphoma
Beyond the preview
Go deeper on NCT00035022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00035022.